CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Eratrectinib

investigational drug

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 20, 2026
Entity authorityQ140529164 ↗
Source-derived summary

Eratrectinib is an investigational new drug that is being developed by Jiangsu Vcare Pharmatech for the treatment of solid tumors. It is a Trk receptor antagonist targeting specifically TRKA, TRKB and TRKC.

It has been approved in June 2026 for use in treating for solid tumors in China.

Editorial summary

This brief starts where responsible research should: with the source description of “Eratrectinib” as investigational drug. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2026—that can be checked directly. The selected authority fields contribute no independent date. The account is most persuasive where Eratrectinib, investigational and drug can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the general reference register because the source frames it as investigational drug. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 20, 2026. The linked authority identifier is Q140529164. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2026.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Eratrectinib”, its source revision and the description used here.
  2. Expand the search: follow Eratrectinib primary sources, Eratrectinib archive and Eratrectinib research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Eratrectinib”?
  2. Which institution is responsible for the underlying evidence?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Eratrectinib” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.